Certara (NASDAQ:CERT) Releases FY 2025 Earnings Guidance

Certara (NASDAQ:CERT) issued an update on its FY 2025 earnings guidance on Friday morning. The company provided earnings per share guidance of 0.450-0.470 for the period, compared to the consensus earnings per share estimate of 0.390. The company issued revenue guidance of $415.0 million-$420.0 million, compared to the consensus revenue estimate of $418.4 million.

Certara Stock Up 0.3%

Certara stock opened at $8.99 on Friday. The stock has a market cap of $1.43 billion, a PE ratio of 128.49 and a beta of 1.46. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.09 and a quick ratio of 2.09. The stock’s fifty day moving average is $9.78 and its two-hundred day moving average is $10.71. Certara has a 1-year low of $8.02 and a 1-year high of $15.69.

Certara (NASDAQ:CERT) last released its quarterly earnings data on Thursday, November 6th. The company reported $0.14 EPS for the quarter, beating analysts’ consensus estimates of $0.11 by $0.03. The business had revenue of $104.62 million for the quarter, compared to the consensus estimate of $104.53 million. Certara had a return on equity of 5.18% and a net margin of 2.62%.During the same quarter in the prior year, the business posted $0.13 EPS. Certara has set its FY 2025 guidance at 0.450-0.470 EPS. On average, sell-side analysts expect that Certara will post 0.28 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on CERT shares. Barclays cut their price objective on shares of Certara from $14.00 to $13.00 and set an “overweight” rating on the stock in a report on Monday, December 15th. Craig Hallum started coverage on shares of Certara in a research note on Monday, September 29th. They set a “buy” rating and a $16.00 price target on the stock. Wall Street Zen raised shares of Certara from a “hold” rating to a “buy” rating in a research report on Monday, November 24th. Weiss Ratings restated a “sell (d+)” rating on shares of Certara in a research note on Monday. Finally, Morgan Stanley dropped their price objective on Certara from $16.00 to $12.00 and set an “equal weight” rating on the stock in a report on Thursday, December 18th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Certara presently has a consensus rating of “Moderate Buy” and a consensus price target of $12.91.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Osaic Holdings Inc. raised its holdings in shares of Certara by 50.7% in the second quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock valued at $41,000 after buying an additional 1,175 shares during the last quarter. Tower Research Capital LLC TRC increased its position in Certara by 499.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,917 shares of the company’s stock valued at $69,000 after acquiring an additional 4,930 shares during the period. Canada Pension Plan Investment Board purchased a new stake in Certara during the 2nd quarter valued at approximately $83,000. Russell Investments Group Ltd. lifted its position in Certara by 5,083.8% during the 3rd quarter. Russell Investments Group Ltd. now owns 10,886 shares of the company’s stock worth $133,000 after acquiring an additional 10,676 shares during the period. Finally, Corient Private Wealth LLC lifted its position in Certara by 11.7% during the 2nd quarter. Corient Private Wealth LLC now owns 12,362 shares of the company’s stock worth $144,000 after acquiring an additional 1,295 shares during the period. 73.96% of the stock is currently owned by institutional investors and hedge funds.

About Certara

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.